Repare Therapeutics

Repare Therapeutics company information, Employees & Contact Information

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We use our genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Our company was founded in 2016 by field-leading academics to systematically employ synthetic lethality insights and platforms and develop new precision oncology medicines. For more information, please visit www.reparerx.com. Scam Prevention Notice It has come to our attention that individuals posing as representatives of Repare Therapeutics have been engaging in fraudulent recruiting activities, offering fake job opportunities to unsuspecting candidates. These scams are designed to deceive job seekers into providing personal information or financial details under false pretenses. Please note that we will only contact you about a position that is posted on our careers page and official email communications from Repare employees will only come from a @reparerx.com email. Repare has a formal process which includes candidate application through the Repare career page (https://www.reparerx.com/careers/). If the job is not posted on the official Repare Therapeutics careers page, then it is not a legitimate position. If you have any questions or concerns regarding job opportunities at Repare Therapeutics, please don't hesitate to reach out to our HR department directly via Contact Us section (https://www.reparerx.com/contact/). Thank you for your vigilance and understanding.

Company Details

Employees
102
Founded
-
Address
Montreal, Quebec, Ca
Email
in****@****erx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Montreal.
HQ
Montreal, Quebec
Looking for a particular Repare Therapeutics employee's phone or email?

Repare Therapeutics Questions

News

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics CRISPR Medicine News

Scalable Synthesis of Lunresertib, a Selective PKMYT1 Inhibitor - ACS Publications

Scalable Synthesis of Lunresertib, a Selective PKMYT1 Inhibitor ACS Publications

Phase 1 Topline: Repare's RP-1664 Shows Preliminary Safety, Antitumor Activity — Poster Oct 25 - Stock Titan

Phase 1 Topline: Repare's RP-1664 Shows Preliminary Safety, Antitumor Activity — Poster Oct 25 Stock Titan

Repare Therapeutics Appoints Steve Forte CEO - citybiz

Repare Therapeutics Appoints Steve Forte CEO citybiz

Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib CRISPR Medicine News

Repare Therapeutics Secures Massive $267M Cancer Drug Deal, Shifts Focus to Two Promising Phase 1 Trials - Stock Titan

Repare Therapeutics Secures Massive $267M Cancer Drug Deal, Shifts Focus to Two Promising Phase 1 Trials Stock Titan

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions - CRISPR Medicine News

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment - CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment CRISPR Medicine News

Top Repare Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant